Spotlight Session 1 – Wednesday, December 11 5:00 pm – 7:00 pm

**Immunotherapy in Breast Cancer: New Directions**

PD1-04: *Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)*

Veronica Mariotti1, Shou-Ching Tang2, Patrick Dillon3, Alberto Montero4, Andrew Poklepovic5, Susan Melin6, Ibrahim Nuhad7, Petros Nikolakis8, Eugene Kennedy9, Hyo Han10, Roohi Ismail-Khan11, Daniel Bruetman12, Oana Danciu13, Paul Gilman14, Boguslawa Karaszewska13, Krysztof LesIEWSki-Kmak14, Timothy Panelia15, Dhimant Patel16, Malgorzata Suszko-Kazarnowicz17, Fabio Volterra18 and Hatem Soliman1.

1Moffitt Cancer Center, Tampa, FL; 2Augusta University, Augusta, GA; 3University of Virginia, Charlottesville, VA; 4Cleveland Clinic, Cleveland, OH; 5Virginia Commonwealth University, Richmond, VA; 6Wake Forest, Winston-Salem, NC; 7MD Anderson Cancer Center, Houston, TX; 8University Cancer & Blood Center, Athens, GA; 9Thomas Jefferson University, Philadelphia, PA; 10Goshen Hospital, Goshen, IN; 11University of Illinois, Chicago, IL; 12Lankenau Institute, Wynnewood, PA; 13Komed, Konin, Poland; 14Oddział Chemioterapii, Gdynia, Poland; 15University of Tennesee, Knoxville, TN; 16Aurora Medical Center, Green Bay, WI; 17Olszynski Osrodek Onkologiczny, Olsztyn, Poland; 18Eastchester Center for Cancer Care, Bronx, NY

Poster Session 1 – Wednesday, December 11 5:00 pm – 7:00 pm

P1-10-06: *Radiomic measurements of tumor-associated vasculature morphology and function on pretreatment dynamic MRI identifies responders to neoadjuvant chemotherapy*

Nathaniel Braman1, Prateek Prasanna1, Kaustav Bera2, Mehdi Allioui3, Manasa Vulchi3, Maryam Etesami3, Paulette Turk3, Jame Abraham2, Donna Plecha4 and Anant Madabhushi1.

1Case Western Reserve University, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH; 3Yale School of Medicine, New Haven, CT; 4University Hospitals Cleveland Medical Center, Cleveland, OH

P1-17-09: *Cardiotoxicity and overall safety profile of adjuvant chemotherapy in elderly breast cancer patients: A cohort study*

Lorenzo Gervasosi1, Valentina Zanuso1, Marco Cefalì1, Vittorio Fregoni2 and Camillo Porta3.

1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 2University of Pavia, Pavia, Italy; 3RCCS ICS Maugeri, University of Pavia, Pavia, Italy

P1-19-03: *JAVELIN PARP Medley, a Phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts*

Timothy A Yap1, Panagiotis Konstantinopoulos2, Melinda L. Tellis3, Smita Saraykar1, J Thadeus Beck4, Matthew D. Galsky1, Jame Abraham1, David R. Wise5, Mustafa Khasrawa1, Gabor Rubovszky10, Mikhail Dvorkin10, Anil A Joy10, Mateusz Opyrchal12, Daria Stypinski13, Colombe Chappey14, Ross Stewart15, Rossano Cesari16, Anita Scheuber17 and Aditya Bardia18.

1The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2Dana-Farber Cancer Institute, Boston, MA; 3Stanford University School of Medicine, Stanford, CA; 4Highlands Oncology Group, Fayetteville, AR; 5Jain School of Medicine at Mount Sinai, New York, NY; 6Cleveland Clinic, Cleveland, OH; 7NYU Laura and Isaac Perlmutter Cancer Center, New York, NY; 8Northern Cancer Institute, The University of Sydney, Sydney, Australia; 9National Institute of Oncology, Budapest, Hungary; 10Budget Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Russia; 11Federation: Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada; 12Roswell Park Comprehensive Cancer Center, Buffalo, NY; 13Pfizer Inc., Cambridge, MA; 14Pfizer Inc., San Francisco, CA; 15Pfizer Inc., San Diego, CA; 16Pfizer Inc., Milan, Italy; 17Pfizer Inc., Collegeville, PA; 18Massachusetts General Hospital, Boston, MA
P1-20-06: Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial
Jorge Ferrer1, David Carr2, Peter Blumencranz3, Daleela Dodge4, Nayana Dekhnes5, Irene Wapnirs6, Kelly Huntr7, Linsey Golds8, Stephanie Valente9, Peter Beitsch10, Donna Dyess11, Shelly Hawgie12, Lynne Clark13, Beth-Ann Lesnikoski14, Anees Chagpar15, Stephen Karps1, Brian Schlossberg1, Sean Madden2, Manna Chang3, Kate Smith4, David Strasfeld5, W David Lee6 and Barbara Smith7.
1Lumicell, Inc, Newton, MA; 2Novant Health, Winston-Salem, NC; 3Comprehensive Breast Care Center, Clearwater, FL; 4Penn State Hershey Medical Center, Hershey, PA; 5Beaumont Health Royal Oak, Royal Oak, MI; 6Stanford University, Palo Alto, CA; 7University of Texas at MD Anderson, Houston, TX; 8Beaumont Health Troy, Troy, MI; 9Cleveland Clinic, Cleveland, OH; 10Dallas Breast Center, Dallas, TX; 11University of South Alabama, Mobile, AL; 12Duke University, Durham, NC; 13CHI Franciscan Breast Surgery, Tacoma, WA; 14Baptist MD Anderson Cancer Center, Jacksonville, FL; 15Yale University, New Haven, CT; 16Lahey Medical Center, Burlington, MA; 17Massachusetts General Hospital, Boston, MA

Poster Session 2 – Thursday, December 12 7:00 am – 9:00 am
P2-04-01: Cyclin dependent kinase 7 (CDK7) inhibition promotes genomic instability and mitotic catastrophe in triple negative breast cancer
Bryan M Webb1, Melyssa Shively1, Katrina Piemonte2, Jennifer M Sahni1 and Ruth A Keri2.
1Case Western Reserve University School of Medicine, Cleveland, OH; 2New York University School of Medicine, New York, NY

P2-13-15: Factors associated with triggering events on the PREVENT trial at 2 years post-operatively
Sheila Hedden Ridner1, Mary S Dietrich2, Chirag Shah3 and Frank Vicini4.
1Vanderbilt University, Nashville, TN; 2Cleveland Clinic, Cleveland, OH; 321st Century Oncology, Farmington Hills, MI

P2-14-13: Comparison of survival outcomes between treatment with endocrine therapy and chemoendocrine therapy in patients with invasive lobular carcinoma
Mathew Thomas, Hong Li, Jame Abraham, Halle CF Moore5, G Thomas Budd, Alberto J Montero and Megan L Kruse.
Cleveland Clinic, Cleveland, OH

Spotlight Session 8 – Thursday, December 12 7:00 am – 9:00 am
The Metastatic Landscape – Drug Resistance and Metastasis
PD8-09: Genome-scale systems biology analyses reveal potentially targetable signaling networks in breast cancer brain metastases
Hannah Elizabeth Hill, Salendra Singh1, Kristy Miskimen2, Paula Silverman1, Jill Barnholtz-Sloan3, Andrew Sloan4, Hannah Gilmore5 and Vinay Varadan6.
1Case Comprehensive Cancer Center, Cleveland, OH; 2Case Western Reserve University, Cleveland, OH; 3University Hospitals Cleveland Medical Center, Cleveland, OH

Poster Session 3 – Thursday, December 12 5:00 pm – 7:00 pm
P3-02-15: Integrin α2 promotes stemness and lung metastasis in triple negative breast cancer
Valery Adorno-Cruz1, Andrew Hoffmann2, Xia Liu2, Ruth Keri3 and Huiping Liu2.
1Case Western Reserve University, Cleveland, OH; 2Northwestern University, Chicago, IL

P3-08-35: Reassessment of traditional oncotype scoring using TAILORx criteria: A large institutional review
Akisha Glasgow, Philip Bomiesl, Paula Silverman, Hannah Gilmore1 and Aparna Harbhajanka.
University Hospitals Cleveland Medical Center, Cleveland, OH

P6-08-66: Metaplastic breast cancer in patients older than 65 years
Johnny Chahine, Bicky Thapa, Xuefei Jia and Abdo Haddad.
Cleveland Clinic Foundation/Fairview Hospital, Cleveland, OH
Spotlight Session 9 – Friday, December 13 7:00 am – 9:00 am

**Detection and Treatment Response Assessment**

PD9-03: A combination of intra- and peri-lesional deep learning classifiers from multiple views enables accurate diagnosis of architectural distortion malignancy with digital breast tomosynthesis

Tristan Maidment1, Nathaniel Braman2, Yijiang Chen, Farhad Mehrkhani1, Uliyyana Yankevich1, Donna Plecha2 and Anant Madabhushi1.

1Case Western Reserve University, Cleveland, OH; 2University Hospitals, Cleveland, OH

Poster Session 4 – Friday, December 13 7:00 am – 9:00 am

P4-10-3: Validation of neural network approach for the prediction of HER2-targeted neoadjuvant chemotherapy response from pretreatment MRI: A multi-site study

Nathaniel Braman1, Mohammed El Adouis1, Manasa Vulchis1, Paulette Turks1, Maryam Etesamis, Pingfu Fu1, Stylianos Drissi2, Vinay Varadan1, Donna Plecha2, Mohammed Benjelloun2, Jame Abrahams2 and Anant Madabhushi1.

1Case Western Reserve University, Cleveland, OH; 2University Hospitals, Cleveland, OH; 3Yale School of Medicine, New Haven, CT; 4Institut Jules Bordet, Brussels, Belgium; 5University Hospitals Cleveland Medical Center, Cleveland, OH; 6University of Mons, Mons, Belgium

P4-17-04: Male breast cancer: Clinico-pathological characteristics from the national cancer database (NCDB)

Elizabeth Blessing Elimimian, Leah Elson, Hong Liang and Zeina Nahleh.

Cleveland Clinic Florida, Weston, FL

Poster Session OT3 – Surgery – Friday, December 13 5:00 pm – 7:00 pm

OT3-06-02: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer

Kate Smith1, Jorge Ferrer1, David Carr2, Peter Blumencranz3, Daleela Dodge4, Nayana Dekhnes4, Irene Wapnir5, Kelly Hunt7, Linsey Golda6, Stephanie Valente6, Peter Beitsch4, Donna Dyess6, Shelly Hwang12, Lynne Clark13, Beth-Ann Lesnikoski14, Anees Chagpar15, Stephen Karpus15, Brian Schlossberg16, Livia Gylameti17 and Barbara Smith17.

1Lumicell, Inc, Newton, MA; 2Navant Health, Winston-Salem, NC; 3Comprehensive Breast Care Center, Clearwater, FL; 4Penn State Hershey Medical Center, Hershey, PA; 5Beaumont Health Royal Oak, Royal Oak, MI; 6Stanford University, Palo Alto, CA; 7University of Texas at MD Anderson, Houston, TX; 8Beaumont Health Troy, Troy, MI; 9Cleveland Clinic, Cleveland, OH; 10Dallas Breast Center, Dallas, TX; 11University of South Alabama, Mobile, AL; 12Duke University, Durham, NC; 13CHI Franciscan Breast Surgery, Tacoma, WA; 14Baptist MD Anderson Cancer Center, Jacksonville, FL; 15Yale University, New Haven, CT; 16Lahey Medical Center, Burlington, MA; 17Massachusetts General Hospital, Boston, MA

Poster Session 5 – Friday, December 13 5:00 pm – 7:00 pm

P5-06-15: Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS)

Haojia Li1, Kaustav Bera1, Hannah Gilmore1, Zelin Zhang3, Jack Cuzick4, Mangesh A Thorat6 and Anant Madabhushi7.

1Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH; 2University Hospitals Cleveland Medical Center, Cleveland, OH; 3Nanjing University of Information Science and Technology, Jiangsu Key Laboratory of Big Data Analysis Technique, Nanjing, China; 4Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; 5School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom; 6Case Western Reserve University, Department of Biomedical Engineering; 7Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH

P5-06-16: Histomorphometric measure of disorder of collagen fiber orientation is associated with risk of recurrence in ER+ breast cancers in ECOG-ACRIN E2197 and TCGA-BRCA

Haojia Li1, Kaustav Bera1, Hannah Gilmore1, Nancy E Davidsom5, Lori J Goldstein4 and Anant Madabhushi7.

SABCS 2019
PS-12-12: Prospective evaluation of adherence to adjuvant aromatase inhibitor (AI) therapy among Hispanic/Latino women with breast cancer (BC) living in the border city of El Paso, Texas
Alexander Philipovskiy, Aleli Campbell, Brenda Castillo, Rosalinda Heydarian, Sumit Gaur, Alok Dwivedi and Zeina Nahleh.
Texas Tech University Health Science Center, El Paso, TX; University of Texas at El Paso, El Paso, TX; Texas Tech University Health Science Center, Paul L. Foster School of Medicine, El Paso, TX; Cleveland Clinic Florida, Maroone Cancer Center, Weston, FL

Poster Session 6 – Saturday, December 14 7:00 am – 9:00 am
P6-10-15: Optoacoustic imaging features correlate with breast cancer clinicopathological prognostic factors
UT Southwestern, Dallas, TX; Seno Medical Instruments, San Antonio, TX; Yale School of Medicine, New Haven, CT; Northwestern University, Chicago, IL; Boston Biostatistics Research Foundation, Framingham, MA; Virginia Biomedical Laboratories, Wirtz, VA; University of Texas Health Science Center at San Antonio, San Antonio, TX; Cleveland Clinic, Cleveland, Ohio, Cleveland, OH